[曲妥珠单抗-美坦新偶联物（T-DM1）在乳腺癌中的临床研究进展]
[Clinical research progress of T-DM1 in breast cancer].
作者信息
Li L X, Ma F
机构信息
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
出版信息
Zhonghua Zhong Liu Za Zhi. 2021 Jan 23;43(1):92-97. doi: 10.3760/cma.j.cn112152-20201112-00980.
Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate (ADC) composed of trastuzumab, a linker, and a microtubule inhibitor. T-DM1 combines the highly effective targeting of antibody with the high anti-tumor activity of cytotoxic drugs, while reduces the off-target toxic side effects of cytotoxic drugs. T-DM1 has been applied in neoadjuvant therapy of HER2-positive breast cancer and rescue treatment of advanced breast cancer, greatly improves the prognosis of breast cancer patients. More and more clinical trials of T-DM1 for HER2 breast cancer and other solid tumors are ongoing, and more positive results are expected.
ado曲妥珠单抗（T-DM1）是一种抗体药物偶联物（ADC），由曲妥珠单抗、一个连接子和一种微管抑制剂组成。T-DM1将抗体的高效靶向性与细胞毒性药物的高抗肿瘤活性相结合，同时减少了细胞毒性药物的脱靶毒副作用。T-DM1已应用于HER2阳性乳腺癌的新辅助治疗和晚期乳腺癌的挽救治疗，极大地改善了乳腺癌患者的预后。越来越多关于T-DM1用于HER2乳腺癌和其他实体瘤的临床试验正在进行，预计会有更多阳性结果。
Zotero 插件